Maxim analyst Jason McCarthy lowered the firm’s price target on Cellectar Biosciences (CLRB) to $1 from $7 and keeps a Buy rating on the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLRB:
- Biotech Alert: Searches spiking for these stocks today
- Cellectar Biosciences Strategic Shift and Workforce Reduction
- Cellectar Biosciences downgraded to Perform from Outperform at Oppenheimer
- Cellectar Biosciences trading resumes
- Cellectar Biosciences reports strategic reprioritization, reduces headcount 60%